Roivant Sciences, Inc.
93 articles with Roivant Sciences, Inc.
-
Roivant Provides Corporate Updates
6/9/2021
Datavant and Ciox Health have signed a definitive merger agreement - Combined company positioned to solve the challenge of health data fragmentation.
-
The $7 billion transaction by Datavant with Ciox Health will be the nation's largest "neutral and secure health data ecosystem."
-
Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology
5/3/2021
- Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors including Sumitomo Dainippon Pharma and Palantir Technologies
-
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
-
Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.
-
Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics
2/26/2021
Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant's drug discovery capabilities
-
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
-
Its potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
-
Ramaswamy told shareholders the move was to separate himself from Roivant’s day-to-day operations in part due to his “increasing public engagement.”
-
Roivant Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders advanced into preclinical development
-
Roivant Unveils Targeted Protein Degradation Platform
12/7/2020
Acquisition of Oncopia Therapeutics and research collaboration with lab of Dr. Shaomeng Wang at the University of Michigan to add diverse pipeline of current and future compounds
-
Roivant Announces Protein Degradation Platform Using VantAI Against Difficult Drug Targets
12/7/2020
Roivant Sciences announced its targeted protein degradation platform, with its first pipeline candidate expected to enter the clinic in 2021. -
Roivant Provides Updates for Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
5/13/2020
Roivant Sciences today announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial evaluating the impact of intravenous (IV) treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.
-
BioSpace Global Roundup, April 23
4/23/2020
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines. -
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
4/15/2020
- BREATHE is an adaptive, randomized, double-blind, placebo-controlled trial expected to enroll up to 270 patients, with a planned interim analysis - FDA has agreed that this study could support registration if successful - This is the first pivotal study for an anti-GM-CSF therapy known to initiate dosing in COVID-19 patients - GM-CSF is a pro-inflammatory cytokine up-regulated in COVID-19 patients at risk of developing Acute Respiratory Distress Syndrome (ARDS)
-
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
-
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
3/18/2020
Roivant Sciences today announced that it has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
-
Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring
1/13/2020
Lokavant has entered into multi-year enterprise license agreement with Parexel
-
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
-
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.